World Health Organization finally has an approved vaccine against Ebola

Henrietta Brewer
November 15, 2019

The Congo Ebola outbreak since past year has killed more than 2,100 people, making it the second-largest Ebola outbreak in history since the 2013-16 epidemic in West Africa that killed more than 11,300. "We at Merck are honored to participate in a aspect in Ebola outbreak response endeavours and we continue to be dedicated to our associates and the people we provide". It's now getting made use of within the ongoing outbreak within the Democratic Republic of Congo centered on a "compassionate use" protocol. The outbreak is the second-major recorded, surpassed only by the 2014 West African outbreak that prompted extra than 11,000 deaths and 28,000 cases.

"The EU is supporting global efforts to combat Ebola on all fronts, from vaccine development to delivering humanitarian aid on the ground", EU Ebola Coordinator Christos Stylianides said in a statement dated November 10.

The European Commission approved the shot after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended its approval in October.


The vaccine has however not yet been licensed, but World Health Organization is bolstering the process after publishing a roadmap to the vaccine's licensing and roll-out in critical countries.

In the US, the Food and Drug Administration (FDA) still has the vaccine under "priority review", with an answer expected next year.

The current outbreak in the DRC has killed almost 2,200 since August 2018, causing almost 3,300 cases. It becomes a major step forward in saving lives in Africa and beyond, European Commissioner Vytenis Andriukaitis said in a statement Sunday.


Researchers at the the Public Health Agency of Canada's National Microbiology Laboratory originally developed the vaccine and licensed it to NewLink Genetics.

The firm celebrated the vaccine's approval Monday. Merck licensed the vaccine amid the 2014 outbreak and developed it with numerous partners. Another vaccine developed by Janssen and the Danish company Bavarian Nordic is now under review by the EMA and the companies expect to receive market approval in 2020. "It is a historic milestone and a testament to the power of science, innovation and public-private partnership", said Kenneth C. Frazier, chairman and chief executive officer, Merck.

In the meantime, the Planet Health and fitness Firm announced Tuesday, November 12 that it has "prequalified" Ervebo, signaling to member nations that the vaccine meets WHO requirements for security, excellent, and effectiveness.


"WHO, with the support of EMA, has worked closely with many African regulators who have indicated they will quickly license the vaccine following the WHO recommendation", the world body said.

Other reports by iNewsToday

FOLLOW OUR NEWSPAPER